A Win For Translate Bio, Inc.
Wed, Jun 12, 2024 at 07:30 PM
Translate Bio, Inc. (TBIO:NASDAQ) jumped higher at $4.34, representing a gain of 37.8%. On Wed, Jun 12, 2024, TBIO:NASDAQ hit a New 2-Week High of $4.34. From Wed, May 29, 2024, the stock recorded 50.00% Up Days and 54.55% Green Days
The stock spiked on Fri, Feb 23, 2024 at $15.46 with a volume of 1M+.
About Translate Bio, Inc. (TBIO:NASDAQ)
Translate Bio Inc is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, for the treatment of cystic fibrosis (CF) and MRT5201, for the treatment of ornithine transcarbamylase (OTC) deficiency.
Top 10 Gainers:
- NYSE Tick Pilot Test Sym-Contro (NTEST:NYSE), 867.6%
- DDC Enterprise Limited Class A (DDC:NYSEMKT), 198.1%
- Longeveron Inc. (LGVN:NASDAQ), 120.73%
- Direct Digital Holdings Inc. (DRCT:NASDAQ), 63.17%
- Unico American Corporation (UNAM:NASDAQ), 50%
- JIADE LIMITED (JDZG:NASDAQ), 38.83%
- Translate Bio, Inc. (TBIO:NASDAQ), 37.78%
- Mediaco Holding Inc. (MDIA:NASDAQ), 37.11%
- Avidity Biosciences Inc. (RNA:NASDAQ), 32.64%
- Linkage Global Inc (LGCB:NASDAQ), 31.11%